Peters on Diabetes

 
 

  • IDF 2021 100 Years of Insulin, but Millions Still Without Access   As we celebrate a century of insulin, we should not forget that many around the world can't afford this life-saving treatment.
  • EASD 2021 Final Roadmap on Type 1 Diabetes Management in Adults   Anne Peters, MD, discusses the consensus statement on managing type 1 diabetes in adults from the American Diabetes Association and the European Association for the Study of Diabetes.
  • Metformin, Then What? More Findings From the GRADE Study   Dr Anne Peters discusses updated results from the GRADE study that were presented at the 2021 European Association for the Study of Diabetes (EASD) meeting.
  • CGM in Type 2 Diabetes: What I Learned From the MOBILE Study   Anne Peters discusses the benefit of CGM in patients with type 2 diabetes on basal insulin, adding that there is much to be done in educating both patients and healthcare professionals about CGM.
  • ADA 2021 New Guidelines for Type 1 Diabetes in Adults: An Overview   Dr Anne Peters summarizes and gives highlights from the new ADA/EASD draft guidelines for the management of type 1 diabetes in adults.
  • All About Wegovy for Weight Loss   Anne Peters talks about the newly approved semaglutide (Wegovy) for weight loss -- the various trials, indications and warnings, dosing, and expectations.
  • Peters on Tirzepatide: 'Impressive, but We Need to Know More'   Dr Anne Peters discusses tirzepatide and the topline results from the SURPASS trials.
  • Updates on Semaglutide for Weight Loss, From ENDO 2021   Dr Anne Peters discusses updates from the STEP trials that were presented at ENDO 2021.
  • The Omnipod 5 System: Trial Results From ENDO 2021   Find out why Dr Anne Peters was 'incredibly excited' to see data presented from the Omnipod 5 clinical trials.
  • SGLT2 Inhibitors in T1D: 'People Are Using Them Now'   Dr Anne Peters talks about what you need to know regarding off-label use of SGLT2 inhibitors in type 1 diabetes.
  • Managing Pregnancy in T1D: 'One of the Hardest Things We Do'   Dr Anne Peters discusses blood glucose targets and continuous glucose monitoring in pregnant patients with type 1 diabetes.
  • "Heart" of the New ADA Guidelines: Pharmacologic Approaches   Dr Anne Peters continues her overview of the ADA 2021 Standards of Care, focusing on the updates to pharmacologic management of glycemia.
  • Key Changes to the 2021 ADA Standards of Care   Dr Anne Peters provides an overview of important changes to the first half of the ADA 2021 Standards of Care.
  • ADA Guidelines: How Do They Come About?   Updating the ADA guidelines is a rigorous and formal process, with review of evidence and much consensus, says Dr Anne Peters.
  • A COVID-19 and Diabetes Update From Anne Peters   How are patients faring with the changes to diabetes care during the pandemic? Dr Anne Peters gives an update and highlights areas that need more focus.
  • EASD 2020 What Is LADA and How Should We Treat It?   A new consensus statement on LADA, or latent autoimmune diabetes in the adult, attempts to define this perplexing disease and give guidance on management.
  • EASD 2020 'Good News' From the FDA on Dulaglutide, Canagliflozin   Two label changes from the FDA mean good news for patients with diabetes, says Dr Anne Peters.
  • EASD 2020 Insulin Updates From EASD 2020   Dr Anne Peters discusses recent data presented at the EASD meeting on ultra rapid-acting and once-weekly insulins.
  • Off to College With T1D in the COVID Era: How to Prepare   For young people with type 1 diabetes facing college for the first time, there's much to consider, says Dr Anne Peters.
  • Irl Hirsch Reviews ADA Highlights With Anne Peters   Drs Anne Peters and Irl Hirsch talk about newer insulins, the newly approved CGM device, and the highs and lows of attending a virtual conference.
  • Not Just About Blood Sugar: 'He Died Because He Lost His Job'   Dr Anne Peters discusses the effect of glycemic control on COVID outcomes and how economic pressures can further put patients with diabetes at risk.
  • Virtual Reality: Diabetes Care During COVID-19 and Beyond   Dr Anne Peters discusses the new normal of virtual reality and her personal experiences with telehealth.
  • COVID-19 and Diabetes: Patterns Emerge   Dr Anne Peters discusses the patients with diabetes who will need the most aggressive outpatient care when infected with COVID-19.
  • Diabetes and COVID-19: Three Patient Cases   How might COVID-19 affect patients with well-controlled type 1 or type 2 diabetes? Dr Anne Peters comments on three patient cases.
  • 'Everyone With Diabetes' Must Prepare for COVID-19   How will COVID-19 affect people with diabetes? Many unanswered questions remain, but there's much we can still do to prepare our patients, says Dr Anne Peters.
  • 2020 ADA Standards: A 'New Concept' in Treating T2D   Dr Peters discusses the updates to the ADA Standards of Care on the pharmacologic treatment of type 2 diabetes.
  • New ADA Standards: Promoting Health   From alternative insulins to diabetes technology, Dr Anne Peters highlights some changes to the 2020 ADA Standards of Medical Care in Diabetes.
  • Emergency Preparedness With Diabetes: Two Rules   Dr Anne Peters has two plans for making sure life-saving insulin and other necessities for diabetes are at the ready in case of evacuation or emergency.
  • Oral Semaglutide Brings GLP-1s to Primary Care   With similar benefits and risks as its injected counterpart, oral semaglutide's greatest benefit may be the ability to expand its use to primary care.
  • 'Better Glycemic Control Than I've Ever Seen'   Two fundamental changes in the management of type 1 diabetes has Dr Peters seeing excellent glycemic control in her patients.
  • Use Apps for Diabetes, but With Care   With the multitude of digital apps available for patients with diabetes, how do you know which ones are safe to use?
  • Using Newer Diabetes Agents: Assess the Most Pressing Need   In patients with diabetes who have known CVD, heart failure, or CKD, the most pressing need is to start an agent that will lower their associated risks, says Anne Peters.
  • Nasal Glucagon a 'Huge Advance' for Caregivers   Treating a loved one who is having an episode of severe hypoglycemia can be a frightening experience. Dr Anne Peters discusses the promising use of recently approved nasal glucagon.
  • Reducing Kidney and CV Complications in Diabetes   Kidney and cardiovascular disease are linked epidemiologically. Prof Rossing reviews potential new therapies with Dr Peters but notes that there is room for improvement in basic practice.
  • ACC Empowers Cardiologists to Use Diabetes Drugs for Heart Disease   The ACC Expert Consensus Pathway puts cardiologists on track to use novel diabetes drugs to prevent heart failure in high-risk patients, says Dr Anne Peters.
  • Nutrition Therapy for Adults With Diabetes or Prediabetes   Dr Anne Peters discusses the new guidelines for nutrition therapy for adults with diabetes or prediabetes.
  • CREDENCE Shifts Our Thinking About SGLT2 Inhibitors   The CREDENCE trial allows us to start thinking of SGLT2 inhibitors as drugs for preserving renal function, independent of other parameters, says Anne Peters.
  • What's New in the 2019 Standards of Medical Care in Diabetes   From telemedicine to patient education and lifestyle management, Dr Peters highlights key changes to this year's ADA standards for diabetes care.
  • Teaching Patients How to Use Inhaled Insulin   Dr Anne Peters says that the key to getting patients to comfortably use inhaled insulin is in the teaching. Mark Harmel demonstrates how.
  • Putting the ADA/EASD Glycemic Management Algorithm to Use   The recent ADA/EASD guideline on managing hyperglycemia in T2D is complicated and may seem daunting. Dr Anne Peters simplifies and reviews the key frames of the guideline.
  • Making the Switch: When Your Patient Can't Afford Insulin   For many patients, analogue insulin is simply unaffordable, but using non-analogue insulin can get complicated. Dr Anne Peters shares her tips and tricks for making a safe transition.
  • Cardiovascular Outcomes Trials Give 'Comforting' Results   Dr Anne Peters gives us her take on the recent CARMELINA, DECLARE-TIMI, and REWIND trials and their cardiovascular outcomes.
  • 'Life Behind the 8-Ball': Kids With Type 2 Diabetes   Especially in underserved areas of Mississippi, children with type 2 diabetes face an uphill battle, and clinicians have to arm them appropriately for the fight.
  • 'Really Good' New Guidelines for T2 Diabetes   Dr Anne Peters applauds the latest changes to guidelines that put cardiovascular risk at the forefront of type 2 diabetes management.
  • New Diabetes Guidelines Already Outdated?   The ACP reviewed relevant studies but came to conclusions 'not germane to the way we treat patients with type 2 diabetes today,' says Dr Anne Peters.
  • Refer Medicare Patients for Free Diabetes Prevention Program   A new Medicare benefit can help patients prevent diabetes and improve other aspects of their health, says Dr Anne Peters.
  • New Diabetes Guidelines Fail to Guide   An effort to encourage individualized treatment choices may muddy the therapy waters, says Dr Peters.
  • 'Now Is the Time to Learn' About CGM   The FreeStyle Libre, a newly approved device for continuous glucose monitoring, is a big advance for people with diabetes who want to avoid finger sticks, says Dr Anne Peters.
  • Ultra-fast Insulins Curb Mealtime Spikes   Faster-acting insulins are especially beneficial for patients on continuous glucose monitors who are keeping track of glucose peaks and valleys.
  • Tips for Demystifying Injections in Diabetes   Dr Anne Peters demonstrates how she teaches injection techniques to patients with diabetes.
  • Helping Diabetes Patients Exercise Without Fear   Managing blood sugar during and after exercise can be challenging, but clinicians can help patients avoid highs and lows.
  • Two 'Incredibly Useful' Tools for Managing Diabetes   Dr Anne Peters demonstrates two continuous glucose monitors--one that provides blood glucose values in real time, and one that lets physicians see 2 weeks of values retrospectively.
  • Two New Combination Injectable Drugs for Type 2 Diabetes   These two new drug combinations will offer better glucose control and simplify the regimen for patients with inadequately controlled type 2 diabetes.
  • The First FDA-Approved Artificial Pancreas System   Dr Peters talks about the first hybrid closed-loop system to be approved by the FDA for the treatment of type 1 diabetes. What is it, how does it work, and what are its limitations?
  • 'Incredibly Exciting': Diabetes Drug With CV Benefits   The FDA's recent addition of a cardiovascular indication for diabetes drug empagliflozin is a significant milestone in diabetes care, says Dr Anne Peters.
  • Prediabetic Feet Deliver Profound Message   The healthy feet of patients with prediabetes represent a special opportunity for medical providers, says Dr Anne Peters.
  • 'We Need to Move Forward': CGM in Diabetes   Sensors matched with insulin pumps beat finger sticks and multiple daily injections, says Dr Anne Peters, so we need 'real science' to determine the value of continuous glucose monitoring in diabetes.
  • Diabetes Drugs: The Latest Good -- and Bad -- News   Dr Anne Peters discusses hot topics in type 2 diabetes treatment: liraglutide shows CV benefits, whereas some SGLT2 inhibitors show renal protection -- and potential harm.
  • New Metformin Rule 'Makes Me Incredibly Happy'   New prescribing guidelines for metformin will make clinicians' lives easier, and they are good for patients, too, says Dr Anne Peters.
  • Wait for It: Diabetes News Eagerly Anticipated   Dr Anne Peters reveals which stories she will be following during the upcoming meeting of the American Diabetes Association in New Orleans.
  • Lower CV Risk -- With a Diabetes Drug   Dr Peters shares a recent case where she prescribed diabetes drugs for the purpose of helping a patient reduce his cardiovascular disease risk.
  • What I Want for Christmas (Next Year)   Dr Anne Peters shares her holiday "wish list" for improvements in diabetes care in the coming year.
  • New Insulins: Benefits and Challenges   Dr Anne Peters explains why new insulin products have clinical benefits and how their higher costs can be managed, especially at the end of the year.
  • How EMPA-REG Has Changed My Practice   The EMPA-REG Outcomes trial found that the diabetes drug empagliflozin was not only safe but it actually provided cardiovascular benefits in high-risk patients.
  • Minimizing DKA Risk With SGLT2 Inhibitors in Type 1 Diabetes   Could dose titration and ketone monitoring make drugs designed for type 2 diabetes safe in type 1 diabetes?
  • Type 2 Diabetes Management: Choosing the Best Therapies   Two experts offer tips for sifting through the many drug options to help patients optimize management of their type 2 diabetes.
  • Demystifying the Glycemic Index: Implications for Practice   What characteristics give a food its glycemic index? What are the benefits of a low-glycemic diet? A nutritionist explains why a low-glycemic-index diet is a shortcut to health.
  • How to Counsel Type 1 Diabetes Patients Who Exercise?   Anne Peters and Bruce Bode discuss the optimal exercise prescription for athletes and patients with type 1 diabetes who want to exercise.
  • 'Understand This Warning': SGLT2s and Ketoacidosis   Dr Anne Peters describes case examples of euglycemic ketoacidosis linked to SGLT2 inhibitors used to treat type 2 diabetes.
  • CV Safety of Diabetes Drugs on ADA 2015 Program   Dr Anne Peters provides background on the cardiovascular risks of four oral diabetes drugs, which will be discussed at the upcoming annual meeting of the American Diabetes Association.
  • Inhaled Insulin: How to Teach Patients   Dr Anne Peters demonstrates the use of the new inhaled insulin device and reminds clinicians what to discuss with patients when initiating this new agent.
  • Tailoring Type 2 Diabetes Treatment: Updated Guidance   Updates to the ADA/EASD guidance on treating hyperglycemia in type 2 diabetes include a discussion of SGLT-2 inhibitors.
  • What's New in the ADA's Latest Diabetes Guidelines?   Dr Anne Peters discusses the changes to the standards of care updated annually by the American Diabetes Association.
  • Anne Peters: Advances in Diabetes, 2014 What were the most important developments in diabetes care this past year?
  • How Promising Is Brown Fat for Weight Loss?   Dr Anne Peters talks with Dr Mattias Blüher about the latest research on brown adipose tissue and the clinical applications under study.
  • 'Constant Feast' Drives Up Diabetes Rates in Saudi Arabia   Dr Anne Peters talks with Dr Aus Alzaid about the high rate of diabetes in Saudi Arabia, and the unique cultural considerations in managing and preventing diabetes in the Middle East.
  • EASD at 50: What's Driving the Future?   Sir George Alberti and Dr. Ele Ferrannini, former presidents of the European Association for the Study of Diabetes, talk with Dr. Anne Peters about how diabetes has evolved over the past 50 years.
  • Helping Diabetes Patients on 'Worst Day of My Life'   Dr. Anne Peters talks with Tami Ross, a leader in diabetes education, about how the healthcare team can help diabetes patients face their new diagnosis and go on to lead healthy, happy lives.
  • What Is an Artificial Pancreas, Really?   Whether you call it 'bionic' or 'artificial,' it's destined to revolutionize diabetes care but still fall short of some patients' expectations. Howard Zisser talks with Anne Peters at ADA 2014.
  • Fascinating Discoveries in Type 2 Diabetes   Dr. Anne Peters talks to Dr. Guy Rutter, who has made some amazing discoveries about beta-cell function in type 2 diabetes.
  • Once-Weekly Dulaglutide Effective for T2DM   Dr. Anne Peters and Dr. Kathleen Dungan discuss results of an open-label trial comparing weekly dulaglutide with daily liraglutide in type 2 diabetes.
  • Congratulations! We're Making Strides in Diabetes Care   Dr. Anne Peters reviews 3 studies that describe the state of diabetes care in the United States, with some encouraging results.
  • Getting to 'A-ha!' With Obese Patients   Dr. Anne Peters shares a patient's story of how she battled obesity and won.
  • Key Points in the ADA's New Diabetes Guidelines   Dr. Anne Peters discusses what's new and what remains important in the American Diabetes Association's 2014 revision of its Standards of Care for diabetes.
  • Anne Peters: The Year in Diabetes Although some of the year's advances represented only small steps for diabetes, they are steps toward improved care and quality of life for millions of patients.
  • How Do New Statin Guidelines Affect Diabetes Care? Although the new guidelines make LDL targets unnecessary, Dr. Anne Peters believes they still may have a place in treating patients with diabetes.
  • Gliptin Safety a 'Good Thing'   'It would have been nice' if the diabetes drugs had actually lowered cardiovascular risk, says Dr. Anne Peters.
  • Top Picks From ADA Dr. Anne Peters reports on the latest developments in the clinical management of diabetes, from the artificial pancreas to insulin, drugs, and combination agents.
  • Type 2 Diabetes in the Hospital: Glucose Management Dr. Kathleen Dungan talks with Dr. Anne Peters about key issues in managing type 2 diabetes patients who are hospitalized and then transitioned back to outpatient care.
  • Transplant Options for Patients With Type 1 Diabetes   Outcomes in whole-pancreas transplants continue to improve, as investigators study less invasive islet transplants. Dr. Michael Rickels discusses the latest developments with Dr. Anne Peters.
  • Beta Cells: 'Where It All Begins' How does dietary fat affect beta cell function in diabetes patients? Dr. Raghu Mirmira talks to Dr. Anne Peters about the research presented at the annual meeting of the American Diabetes Association.
  • AACE Algorithm Offers New Guidance on Managing T2DM   Dr. Anne Peters reviews the latest algorithm from the American Association of Clinical Endocrinologists for treating type 2 diabetes.
  • Canagliflozin: Who May Benefit From New Diabetes Drug?   Dr. Anne Peters discusses the clinical considerations in prescribing this first-in-class drug for type 2 diabetes.
  • An Unusual Case of Type 1 Diabetes -- or Is It Type 2?   Dr. Anne Peters describes her management of a lean Asian man who came to her with a diagnosis of type 1 diabetes.
  • Kazano! New Alogliptin Combos for Type 2 Diabetes   Dr. Anne Peters explains prescribing considerations for the newly approved alogliptin and its combination formulations.
  • What's New in ADA's Latest Diabetes Guidelines?   Dr. Anne Peters discusses the changes to the standards of care updated annually by the American Diabetes Association.
  • CGM: Practical Uses in Diabetes   Dr. Anne Peters discusses the real-life use of continuous glucose monitoring and recent advances in the technology.
  • Insulin for Prediabetes?   Dr. Anne Peters describes her personalized approach to treating a patient with prediabetes, using clinical trial data and the patient's input to come up with an unusual plan.
  • 'Why We Halted Look AHEAD'   Dr. Anne Peters, an investigator for Look AHEAD (Action for Health in Diabetes), explains the reasons for stopping this large national trial and provides perspective for clinicians to share with their patients.
  • How to Use New Type 2 Diabetes Guidelines   Dr. Anne Peters, an author of the ADA/EASD guidance issued earlier this year, offers a step-by-step guide to selecting the right medications for patients with type 2 diabetes.